Expert Perspectives in RVO

In this expert perspective from Hawaiian Eye 2025, Ashkan M. Abbey, MD, discusses an advancement in retinal vein occlusion treatment from 2024 and highlights a treatment in the pipeline for 2025.

In this expert perspective from Hawaiian Eye 2025, W. Lloyd Clark, MD, discusses the use of aflibercept 8 mg in the treatment of retinal vein occlusion.

In this expert perspective from Hawaiian Eye 2025, Roger A. Goldberg, MD, MBA, highlights advancements in the treatment of retinal vein occlusion.

In this expert perspective from Hawaiian Eye 2024, Rishi P. Singh, MD, discusses how the management of retinal vein occlusion will evolve over the next year.

In this expert perspective from Hawaiian Eye 2024, Rishi P. Singh, MD, said one of the biggest changes in retinal vein occlusion has been the advancement in understanding of how many patients are affected by the disease.

In this expert perspective from Hawaiian Eye 2024, Ferhina S. Ali, MD, MPH, discusses expectations for how faricimab will perform in the real world for the treatment of retinal vein occlusion.

In this expert perspective from Hawaiian Eye 2024, Kent W. Small, MD, discusses important developments in the treatment of retinal vein occlusion, or RVO.

In this expert perspective from Hawaiian Eye 2024, Jordan M. Graff, MD, FACS, discusses faricimab for the treatment of retinal vein occlusion.

In this expert perspective from Hawaiian Eye 2024, Roger A. Goldberg, MD, MBA, discusses the significance of the approval of Vabysmo from Genentech for the treatment of retinal vein occlusion.

In this expert perspective from Hawaiian Eye 2024, Roger A. Goldberg, MD, MBA, discusses what to expect for the treatment of retinal vein occlusion, or RVO, in 2024.